MetaVia is trading at $1.16, down 13.51%, amid broad-market weakness on November 5; no company-specific negative catalyst was reported.

  • Nasdaq Composite fell 3.23%, while the S&P 500 declined 1.86%.
  • MetaVia announced positive interim Phase 1 results for DA-1726, including a 68% placebo-adjusted liver-fat reduction after 16 weeks; the release did not explain the stock drop.
  • Intraday volume data was not available in the provided context.